Vijaya Ramesh Selected Research

Vijaya Ramesh Research Topics

Disease

21	Neoplasms (Cancer) 01/2022 - 11/2002
14	Tuberous Sclerosis (Bourneville's Disease) 01/2021 - 11/2003
12	Meningioma (Meningiomas) 01/2021 - 02/2008
6	Neurofibromatosis 2 (Neurofibromatosis Type II) 01/2021 - 11/2004
5	Neurilemmoma (Schwannoma) 01/2021 - 08/2009
4	Neurofibromatoses (Neurofibromatosis) 01/2019 - 02/2010
2	Autism Spectrum Disorder 01/2020 - 03/2013
2	Carcinogenesis 01/2018 - 02/2008
2	Schwannomatosis 06/2017 - 03/2014
2	Chordoma 03/2009 - 09/2004
2	Hamartoma 09/2004 - 11/2003
2	Dystonia (Limb Dystonia) 05/2004 - 02/2003
1	Leukemia 01/2021
1	Frontotemporal Dementia (Semantic Dementia) 01/2021
1	Tauopathies 01/2021
1	Neurodevelopmental Disorders 01/2020
1	Acoustic Neuroma (Acoustic Neurinoma) 01/2020
1	Intellectual Disability (Idiocy) 01/2020
1	Epilepsy (Aura) 01/2020
1	Glioma (Gliomas) 06/2017
1	Neuroblastoma 06/2017
1	Sarcoma (Soft Tissue Sarcoma) 06/2017
1	Weight Gain 10/2015
1	Autistic Disorder (Autism) 03/2013
1	Cognitive Dysfunction 08/2008
1	Movement Disorders (Movement Disorder) 05/2004
1	Inflammation (Inflammations) 02/2003
1	Dystonia musculorum deformans type 1 02/2003
1	Neurologic Manifestations (Neurological Manifestations) 11/2002

Drug/Important Bio-Agent (IBA)

11	trans-sodium crocetinate (crocetin)IBA 01/2021 - 11/2003
11	Neurofibromin 2 (Merlin)IBA 01/2018 - 11/2004
11	Proteins (Proteins, Gene)FDA Link 07/2015 - 02/2003
8	Mechanistic Target of Rapamycin Complex 1IBA 01/2020 - 03/2009
7	Sirolimus (Rapamycin)FDA Link 01/2020 - 08/2008
6	Tuberous Sclerosis Complex 2 ProteinIBA 01/2021 - 11/2002
5	Phosphotransferases (Kinase)IBA 01/2021 - 05/2012
4	Tuberous Sclerosis Complex 1 ProteinIBA 01/2021 - 11/2002
4	TOR Serine-Threonine KinasesIBA 01/2018 - 06/2008
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
3	Mechanistic Target of Rapamycin Complex 2IBA 01/2018 - 05/2012
3	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 07/2015 - 11/2004
2	vistusertibIBA 01/2020 - 07/2015
2	EphA1 Receptor (Eph Receptor)IBA 01/2020 - 01/2018
2	Dasatinib (BMS 354825)FDA Link 01/2020 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 02/2003
2	Mediator ComplexIBA 01/2015 - 11/2007
2	Biological ProductsIBA 08/2008 - 02/2008
2	radixinIBA 08/2005 - 11/2004
1	ChromatinIBA 01/2022
1	Adenosine Triphosphate (ATP)IBA 01/2022
1	LigandsIBA 01/2021
1	brigatinibIBA 01/2021
1	Neuregulin-1 (Neuregulin 1)IBA 01/2021
1	NeuregulinsIBA 01/2021
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2021
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	tau Proteins (tau Protein)IBA 01/2021
1	Therapeutic UsesIBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	Drug CombinationsIBA 01/2018
1	omipalisibIBA 01/2018
1	PanobinostatIBA 01/2018
1	Antineoplastic Agents (Antineoplastics)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 06/2017
1	Uvitex SWN (SWN)IBA 06/2017
1	VimentinIBA 01/2016
1	MTOR InhibitorsIBA 07/2015
1	serum-glucocorticoid regulated kinaseIBA 07/2015
1	FRAX597IBA 07/2015
1	ElementsIBA 02/2011
1	Phosphatidylinositols (Phosphatidylinositol)IBA 08/2009
1	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 03/2009
1	TensinsIBA 03/2009
1	ezrinIBA 11/2004
1	moesinIBA 11/2004
1	Glutamic Acid (Glutamate)FDA Link 05/2004
1	KinesinsIBA 05/2004
1	Mitogen-Activated Protein KinasesIBA 02/2004

Therapy/Procedure

11	Therapeutics 01/2021 - 05/2012
3	Drug Therapy (Chemotherapy) 01/2021 - 02/2010
1	Aftercare (After-Treatment) 01/2018